Reata Pharmaceuticals Garners $60,500,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=21d9b3ba-3a07-4022-b7ba-ce9f48344254 - Date
5/26/2016 - Company Name
Reata Pharmaceuticals - Mailing Address
2801 Gateway Drive Irving, TX 75063 USA - Company Description
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases. - Website
http://www.reatapharma.com - Transaction Type
IPO - Transaction Amount
$60,500,000 - Transaction Round
Undisclosed - Proceeds Purposes
We intend to use the net proceeds from this offering as follows: approximately $30 million to advance the development of bardoxolone methyl through a Phase 3 clinical trial for the treatment of CTD-PAH; approximately $6 million to advance the development of bardoxolone methyl through Phase 2 clinical programs for the treatment of four etiologies of PH-ILD; approximately $15 million to advance the development of omaveloxolone, including completion of the MOXIe and MOTOR Phase 2 clinical trials; and the remainder for working capital and other general purposes, including our preclinical studies and clinical trials, although we have not allocated specific dollar amounts to such purposes. - M&A Terms
